|
Advances in Treatment of Recurrent Ovarian Cancer and Rare Malignant Germ Cell Tumors |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Team-Based Case Review: Hepatocellular Carcinoma |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Updates in the Multidisciplinary Approach for Resectable Gastroesophageal Adenocarcinoma and Peritoneal-Limited Disease |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Expansion of Recommendations for Hereditary Cancers |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Management of Immune Checkpoint Inhibitor-Related Toxicities |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
From Theory to Practice: Building Sustainable, High-Impact Patient Navigation Models |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Innovative Strategies to Improve Patient Access |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Effective and Safe Telehealth Delivery and Remote Patient Monitoring |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Preparing the Oncology Nursing Workforce: Innovative Strategies and Partnerships |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Advances in the Treatment of Non-Metastatic Non-Small Cell Lung Cancer |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Team-Based Case Review: Oligometastatic Prostate, Non-Small Cell Lung, and Colorectal Cancers |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Updates to Management of Multiple Myeloma |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Smoking Cessation for Patients with Cancer: State of the Evidence |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
NCCN Guidelines® Insights - Management of Immunotherapy-Related Toxicities, Version 2.2024 |
1.00 |
11/10/2024 - 12:00am to 11/10/2025 - 12:00am |
|
Newer Approaches to Treatment of Bladder Cancer |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
Facebook
Twitter
LinkedIn
Forward